Opioid Growth Factor (OGF) and Gemcitabine: Novel Treatment for Pancreatic Cancer
Status:
Terminated
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
It is hypothesized that OGF biotherapy may be safely administered in combination with
gemcitabine to individuals with unresectable pancreatic cancer. The study includes two aims,
the first is to evaluate the safety and toxicity of the combination of OGF and gemcitabine
chemotherapy. The second aim of the trial is to study the efficacy of OGF and gemcitabine
when used in combination.
Phase:
Phase 1
Details
Lead Sponsor:
Jill P. Smith Milton S. Hershey Medical Center
Collaborators:
Milton S. Hershey Medical Center National Cancer Institute (NCI) National Institutes of Health (NIH)